Last update Dec. 20, 2022

Nelfinavir Mesylate; Nelfinavir Mesilate (NFV)

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is an HIV protease inhibitor with antiviral activity against HIV. It is used in the treatment of HIV infection and AIDS. Oral administration in two - three daily doses.

It is excreted in breast milk in a very small amount, clinically insignificant.. (Weidle 2011, Rezk 2008, Colebunders 2005)

Nearly 5% of infants whose mothers took it had rash, hyperbilirubinemia, or hepatotoxicity. (Minniear 2012)

The plasma levels of these infants were very low or below the limit of detection. (Weidle 2011)

During lactation other HIV/AIDS treatments are preferable. (Panel 2022, WHO 2016)

See below the information of this related product:


Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Nelfinavir Mesylate; Nelfinavir Mesilate (NFV) in other languages or writings:


Nelfinavir Mesylate; Nelfinavir Mesilate (NFV) belongs to this group or family:


Main tradenames from several countries containing Nelfinavir Mesylate; Nelfinavir Mesilate (NFV) in its composition:


Variable Value Unit
Oral Bioavail. 89 %
Molecular weight 664 daltons
Protein Binding > 98 %
VD 2 - 7 l/Kg
pKa 9.32 -
Tmax 2 - 4 hours
3.5 - 5 hours
M/P ratio 0.1 - 0.2 -
Theoretical Dose 0.03 - 0.05 mg/Kg/d
Relative Dose 0.14 - 0.26 %
Ped.Relat.Dose 0.03 - 0.05 %


  1. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Department of Health and Human Services. 2023 Consulted on June 16, 2023 Abstract Full text (link to original source)
  2. WHO - World Health Organization Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Guideline. 2016 Abstract Full text (link to original source) Full text (in our servers)
  3. CDC - Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV— United States. nPEP Guidelines Update. 2016 Full text (link to original source) Full text (in our servers)
  4. Minniear TD, Zeh C, Polle N, Masaba R, Peters PJ, Oyaro B, Akoth B, Ndivo R, Angira F, Mills LA, Thomas TK. Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission. Pediatr Infect Dis J. 2012 Nov;31(11):1155-7. Abstract
  5. Weidle PJ, Zeh C, Martin A, Lando R, Angira F, Osoga J, Ogindo P, Girde S, Minniear TD, Thomas TK. Nelfinavir and its active metabolite, hydroxy-t-butylamidenelfinavir (M8), are transferred in small quantities to breast milk and do not reach biologically significant concentrations in breast-feeding infants whose mothers are taking nelfinavir. Antimicrob Agents Chemother. 2011 Nov;55(11):5168-71. Abstract Full text (link to original source)
  6. Rezk NL, White N, Bridges AS, Abdel-Megeed MF, Mohamed TM, Moselhy SS, Kashuba AD. Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications. Ther Drug Monit. 2008 Oct;30(5):611-9. Abstract Full text (link to original source)
  7. Colebunders R, Hodossy B, Burger D, Daems T, Roelens K, Coppens M, Van Bulck B, Jacquemyn Y, Van Wijngaerden E, Fransen K. The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk. AIDS. 2005 Nov 4;19(16):1912-5. Abstract Full text (link to original source)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM